Zealand Pharma Reports Part 1 Results of Multiple Ascending Dose Trial for ZP8396 for the Management of Overweight and Obesity
Shots:
- Part 1 of a multiple ascending doses (MAD) trial evaluating the safety, tolerability & clinical effects of ZP8396 (0.6 & 1.2mg, qw for 6wks.) vs PBO in a ratio (7:3) in healthy lean & overweight people
- The results showed mean body weight reductions of 5.3% & 5.1% from baseline at doses of 0.6 & 1.2mg ZP8396 vs 2.6% in PBO, well tolerated with no serious or sev. AEs and no withdrawals
- The company initiated the second part of the MAD trial assessing a longer duration of treatment & higher doses of ZP8396, based on the mild AEs profile observed in part 1 of the trial. The company is expected to present the results from the 6wk. part 1 at a scientific conference in 2023 while the results from the 16wk. part 2 in 2024
Ref: Globenewswire | Image: zealand-pharma
Related News:- Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
